Zoetis Inc. reported second-quarter 2025 revenue of $2.5 billion, a 4% increase over Q2 2024, and 8% organic operational growth. Adjusted net income reached $783 million, or $1.76 per diluted share, representing 10% reported and 13% organic operational growth.
The companion animal segment showed 8% operational growth, with the Simparica franchise growing 17% operationally to $448 million and the Key Dermatology franchise growing 11% operationally to $460 million. However, Librela's U.S. sales declined 16% to $45 million, while Solensia grew 17% to $19 million.
Zoetis reaffirmed its full-year 2025 guidance, projecting revenue between $9.45 billion and $9.6 billion, and adjusted diluted EPS between $6.30 and $6.40. This outlook reflects confidence in the company's strong first-half performance and disciplined execution.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.